Overview

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

A prospective randomised controlled study to evaluate outcomes of the treatment with pradaxa or warfarin for prevention of recurrent DVT in patients with angiographically confirmed acute massive pulmonary embolism undergoIng endovascular mechanical fragmentation and thrombolytic therapy. [RE-SPIRE study]

Phase:

Phase 4

Details

Lead Sponsor:

Meshalkin Research Institute of Pathology of Circulation

Collaborator:

Boehringer Ingelheim

Treatments:

Calcium heparin
Dabigatran
Fibrinolytic Agents
Heparin
Warfarin